In a 12-month study of 207 adults with post-bariatric weight regain, those receiving semaglutide lost 12.92% of their body weight, compared with 8.77% for liraglutide
Eur J Neurosci 12 : 37213728
Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, et al
In 2018, FDA published guidance to 503A pharmacies on what will be considered unauthorized compounding of a product that is essentially a copy of an FDA-approved product, with an exception available when the prescriber documents on the prescription that the compounded drug product produces a significant difference for the identified individual patient. Under the 2018 guidance, FDA generally does not intend to question prescriber determinations that are documented in a prescription or notation. To date, patient-specific GLP-1 compounding activities have often included adding supplemental ingredients to combat side effects of the GLP-1 products or customizing doses, with a significant percentage of prescriptions for customization written by telehealth prescribers
Yes, meal prep works great for GLP-1 users